

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Michael D. Culler et al. Art Unit :
Serial No. : Examiner :
Filed : Herewith
Title : METHODS OF INHIBITING FIBROSIS WITH A SOMATOSTIN AGONIST

Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination, please amend the application as follows:

In the Specification:

On page 1, after the title, insert the following paragraph:

-- Cross Reference to Related Applications

This application is a divisional of application serial number 09/254,097, filed May 10, 1999, now allowed.--

In the Claims:

Cancel claims 144-172 without prejudice.

REMARKS

The present application is a divisional of, and claims priority from, U.S. Patent Application 09/254,097, now allowed. Claims 142 and 143 are now pending.

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No EL224702471US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit January 16, 2001

Signature

Samantha Bell
Typed or Printed Name of Person Signing Certificate

Applicant : Michael D. Culler et al.
Serial No. :
Filed : Herewith
Page : 2

Attorney's Docket No.: 00537-149003 / BPC044A

Prompt examination of this application, as amended, is respectfully requested.

Please apply any other charges to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 1-16-01

Y. Rocky Tsao
Y. Rocky Tsao
Reg. No. 34,053

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

20151725.doc

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Michael D. Culler et al. Art Unit:
Serial No.: Examiner:
Filed : Herewith
Title : METHOD OF INHIBITING FIBROSIS WITH A SOMATOSTATIN
 AGONIST

Box PCT

Assistant Commissioner for Patents
Washington, DC 20231

PRELIMINARY AMENDMENT

Prior to examination, please amend the application as follows:

In the Claims:

Delete claims 1 through 141 and insert new claims 142 through 172.

-- 142. A method of inhibiting fibrosis in a patient said method comprising administering a therapeutically effective amount of somatostatin or a somatostatin agonist to said patient.

143. A method of claim 142, wherein said method comprises administering a therapeutically effective amount of a somatostatin agonist to said patient.

144. A method of claim 143, wherein said fibrosis is in the kidney, in the lung, in the liver, in the skin, of the central nervous system, in bone or bone marrow, in the cardiovascular system, in an endocrine organ and or in the gastro-intestinal system.

"EXPRESS MAIL" Mailing Label Number EL245469797US

Date of Deposit March 1, 1999

I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office To Addressee" with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Jason Kurian

James Blair

145. A method of claim 143, wherein said fibrosis is induced by chemotherapy, induced by radiation, induced by a drug or a combination of drugs, induced by a disease state, induced by an environmental or an industrial factor, induced by an immune reaction, or induced by a wound.

146. A method of claim 143, wherein said somatostatin agonist is administered parenterally.

147. A method of claim 146, wherein said somatostatin agonist is administered in a sustained release formulation.

148. A method of claim 144, wherein said somatostatin agonist is administered parenterally.

149. A method of claim 148, wherein said somatostatin agonist is administered in a sustained release formulation.

150. A method of claim 143, wherein said somatostatin agonist is administered topically or orally.

151. A method according to claim 144 wherein the fibrotic disorder in the kidney is glomerulonephritis, diabetic nephropathy, allograft rejection or HIV nephropathy; the fibrotic disorder in the lung is idiopathic fibrosis or autoimmune fibrosis; the fibrotic disorder in the liver is cirrhosis or veno-occlusive disease; the fibrotic disorder in the skin is systemic sclerosis, keloids, burn scars or eosinophilia-myalgia syndrome and the fibrotic disorder in the central nervous system is intraocular fibrosis.

152. A method according to claim 145 wherein the fibrosis induced by chemotherapy is in the kidney, in the lung, in the liver, in the skin, of the central nervous system, in bone

or bone marrow, in the cardiovascular system, in an endocrine organ or in the gastro-intestinal system.

153. A method according to claim 145 wherein the fibrosis induced by radiation is in the kidney, in the lung, in the liver, in the skin, of the central nervous system, in bone or bone marrow, in the cardiovascular system, in an endocrine organ or in the gastro-intestinal system.

154. A method of inhibiting over-expression of TGF-J which comprises administering to a subject an effective amount of somatostatin or a somatostatin agonist, or a pharmaceutically acceptable salt thereof.


155. A method according to claim 154 wherein a somatostatin agonist or a pharmaceutically acceptable salt thereof is administered.

156. A method according to claim 155 wherein the somatostatin agonist has a higher binding affinity for human somatostatin sub-type receptor 1, has a higher binding affinity for human somatostatin sub-type receptor 2, has a higher binding affinity for human somatostatin sub-type receptor 3, has a higher binding affinity for human somatostatin sub-type receptor 4, or has a higher binding affinity for human somatostatin sub-type receptor 5.

157. A method according to claim 155 wherein the somatostatin agonist has a higher binding affinity for two or more of human somatostatin sub-type receptor 1, human somatostatin sub-type receptor 2, human somatostatin sub-type receptor 3, human

somatostatin sub-type receptor 4 or human somatostatin sub-type receptor 5.

158. A method according to claim 155 wherein the somatostatin agonist is



or a pharmaceutically acceptable salt thereof, wherein

A¹ is a D- or L- isomer of Ala, Leu, Ile, Val, Nle, Thr, Ser, J-Nal, J-Pal, Trp, Phe, 2,4-dichloro-Phe, pentafluoro-Phe, p-X-Phe, or o-X-Phe, wherein X is CH₃, Cl, Br, F, OH, OCH₃ or NO₂;

A² is Ala, Leu, Ile, Val, Nle, Phe, J-Nal, pyridyl-Ala, Trp, 2,4-dichloro-Phe, pentafluoro-Phe, o-X-Phe, or p-X-Phe, wherein X is CH₃, Cl, Br, F, OH, OCH₃ or NO₂;

A³ is pyridyl-Ala, Trp, Phe, J-Nal, 2,4-dichloro-Phe, pentafluoro-Phe, o-X-Phe, or p-X-Phe, wherein X is CH₃, Cl, Br, F, OH, OCH₃ or NO₂;

A⁶ is Val, Ala, Leu, Ile, Nle, Thr, Abu, or Ser;

A⁷ is Ala, Leu, Ile, Val, Nle, Phe, J-Nal, pyridyl-Ala, Trp, 2,4-dichloro-Phe, pentafluoro-Phe, o-X-Phe, or p-X-Phe, wherein X is CH₃, Cl, Br, F, OH, OCH₃ or NO₂;

A⁸ is a D- or L-isomer of Ala, Leu, Ile, Val, Nle, Thr, Ser, Phe, J-Nal, pyridyl-Ala, Trp, 2,4-dichloro-Phe, pentafluoro-Phe, p-X-Phe, or o-X-Phe, wherein X is CH₃, Cl, Br, F, OH, OCH₃ or NO₂;

each R₁ and R₂, independently, is H, lower acyl or lower alkyl; and R₃ is OH or NH₂; provided that at least one of A¹ and A⁸ and one of A² and A⁷ must be an aromatic amino acid; and further provided that A¹, A², A⁷ and A⁸ cannot all be aromatic amino acids.

159. A method according to claim 155 wherein the somatostatin agonist is



H-D-Phe-p-chloro-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH₂;

H-D-Phe-p-NO₂-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;
 H-D-Nal-p-chloro-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;
 H-D-Phe-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-NH₂;
 H-D-Phe-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;
 H-D-Phe-p-chloro-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;
 H-D-Phe-Ala-Tyr-D-Trp-Lys-Val-Ala-J-D-Nal-NH₂;
 D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-b-Nal-NH₂;
 D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-b-Nal-NH₂;
 D-b-Nal-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH₂;
 D-Phe-Cys-Phe-D-Trp-Lys-Thr-Pen-Thr-NH₂;
 D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-OH;
 D-Phe-Cys-Phe-D-Trp-Lys-Thr-Pen-Thr-OH;
 Gly-Pen-Phe-D-Trp-Lys-Thr-Cys-Thr-OH;
 Phe-Pen-Tyr-D-Trp-Lys-Thr-Cys-Thr-OH;
 Phe-Pen-Phe-D-Trp-Lys-Thr-Pen-Thr-OH;
 H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol;
 H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 H-D-Trp-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;
 H-D-Trp-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;
 H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH₂;
 H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;
 Ac-D-Phe-Lys*-Tyr-D-Trp-Lys-Val-Asp-Thr-NH₂, wherein an amide
 bridge is between Lys* and Asp;
 Ac-hArg(Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 Ac-D-hArg(Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 Ac-D-hArg(Bu)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 Ac-D-hArg(Et)₂-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 Ac-L-hArg(Et)₂-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 Ac-D-hArg(CH₂CF₃)₂-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 Ac-D-hArg(CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 Ac-D-hArg(CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH₂;
 Ac-D-hArg(CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHET;
 Ac-L-hArg(CH₂-CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 Ac-D-hArg(CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys(Me)-Thr-Cys-Thr-NH₂;

Ac-D-hArg (CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys (Me) -Thr-Cys-Thr-NHEt;
 Ac-hArg (CH₃, hexyl)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 H-hArg (hexyl)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 Ac-D-hArg (Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHEt;
 Ac-D-hArg (Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH₂;
 Propionyl-D-hArg (Et)₂-Gly-Cys-Phe-D-Trp-Lys (iPr) -Thr-Cys-Thr-NH₂;
 Ac-D-J-Nal-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Gly-hArg (Et)₂-NH₂;
 Ac-D-Lys (iPr) -Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 Ac-D-hArg (CH₂CF₃)₂-D-hArg (CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-
 Thr-NH₂;
 Ac-D-hArg (CH₂CF₃)₂-D-hArg (CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-
 Phe-NH₂;
 Ac-D-hArg (Et)₂-D-hArg (Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 Ac-Cys-Lys-Asn-4-Cl-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Ser-D-Cys-NH₂;
 Bmp-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;
 Bmp-Tyr-D-Trp-Lys-Val-Cys-Phe-NH₂;
 Bmp-Tyr-D-Trp-Lys-Val-Cys-p-Cl-Phe-NH₂;
 Bmp-Tyr-D-Trp-Lys-Val-Cys-b-Nal-NH₂;
 H-D-b-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;
 H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂;
 H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-b-Nal-NH₂;
 H-pentafluoro-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;
 Ac-D-b-Nal-Cys-pentafluoro-Phe-D-Trp-Lys-Val-Cys-Thr-NH₂;
 H-D-b-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-b-Nal-NH₂;
 H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-b-Nal-NH₂;
 H-D-b-Nal-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂;
 H-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂;
 Ac-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂;
 H-D-Phe-Cys-b-Nal-D-Trp-Lys-Val-Cys-Thr-NH₂;
 H-D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH₂;
 cyclo (Pro-Phe-D-Trp-N-Me-Lys-Thr-Phe);
 cyclo (Pro-Phe-D-Trp-N-Me-Lys-Thr-Phe);
 cyclo (Pro-Phe-D-Trp-Lys-Thr-N-Me-Phe);
 cyclo (N-Me-Ala-Tyr-D-Trp-Lys-Thr-Phe);
 cyclo (Pro-Tyr-D-Trp-Lys-Thr-Phe);
 cyclo (Pro-Phe-D-Trp-Lys-Thr-Phe);

cyclo (Pro-Phe-L-Trp-Lys-Thr-Phe) ;
 cyclo (Pro-Phe-D-Trp (F) -Lys-Thr-Phe) ;
 cyclo (Pro-Phe-Trp (F) -Lys-Thr-Phe) ;
 cyclo (Pro-Phe-D-Trp-Lys-Ser-Phe) ;
 cyclo (Pro-Phe-D-Trp-Lys-Thr-p-Cl-Phe) ;
 cyclo (D-Ala-N-Me-D-Phe-D-Thr-D-Lys-Trp-D-Phe) ;
 cyclo (D-Ala-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Phe) ;
 cyclo (D-Ala-N-Me-D-Phe-D-Thr-Lys-D-Trp-D-Phe) ;
 cyclo (D-Abu-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Tyr) ;
 cyclo (Pro-Tyr-D-Trp-t-4-AchxAla-Thr-Phe) ;
 cyclo (Pro-Phe-D-Trp-t-4-AchxAla-Thr-Phe) ;
 cyclo (N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe) ;
 cyclo (N-Me-Ala-Tyr-D-Trp-t-4-AchxAla-Thr-Phe) ;
 cyclo (Pro-Tyr-D-Trp-4-Amphe-Thr-Phe) ;
 cyclo (Pro-Phe-D-Trp-4-Amphe-Thr-Phe) ;
 cyclo (N-Me-Ala-Tyr-D-Trp-4-Amphe-Thr-Phe) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba-Gaba) ;
 cyclo (Asn-Phe-D-Trp-Lys-Thr-Phe) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-NH(CH₂)₄CO) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-b-Ala) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-D-Glu) -OH ;
 cyclo (Phe-Phe-D-Trp-Lys-Thr-Phe) ;
 cyclo (Phe-Phe-D-Trp-Lys-Thr-Phe-Gly) ;
 cyclo (Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gly) ;
 cyclo (Asn-Phe-Phe-D-Trp (F) -Lys-Thr-Phe-Gaba) ;
 cyclo (Asn-Phe-Phe-D-Trp (NO₂) -Lys-Thr-Phe-Gaba) ;
 cyclo (Asn-Phe-Phe-Trp (Br) -Lys-Thr-Phe-Gaba) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe (I) -Gaba) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Tyr (But) -Gaba) ;
 cyclo (Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Pro-Cys) -OH ;
 cyclo (Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Pro-Cys) -OH ;
 cyclo (Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Tpo-Cys) -OH ;
 cyclo (Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-MeLeu-Cys) -OH ;
 cyclo (Phe-Phe-D-Trp-Lys-Thr-Phe-Phe-Gaba) ;

cyclo (Phe-Phe-D-Trp-Lys-Thr-Phe-D-Phe-Gaba) ;
 cyclo (Phe-Phe-D-Trp (5F) -Lys-Thr-Phe-Phe-Gaba) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys (Ac) -Thr-Phe-NH- (CH₂)₃-CO) ;
 cyclo (Lys-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba) ;
 cyclo (Lys-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba) ;
 cyclo (Orn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba) ;
 D-b-Nal-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH₂ ;
 H-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH₂ ;




or D-Phe-cyclo(Cys-Phe-D-Trp-Lys-Thr-Cys)-Thr-ol; or
 a pharmaceutically acceptable salt thereof.

160. A method according to claim 143 wherein the somatostatin agonist has a higher binding affinity for human somatostatin sub-type receptor 1, has a higher binding affinity for human somatostatin sub-type receptor 2, has a higher binding affinity for human somatostatin sub-type receptor 3, has a higher binding affinity for human somatostatin sub-type receptor 4, or has a higher binding affinity for human somatostatin sub-type receptor 5.

161. A method according to claim 143 wherein the somatostatin agonist has a higher binding affinity for two or more of human somatostatin sub-type receptor 1, human somatostatin sub-type receptor 2, human somatostatin sub-type receptor 3, human somatostatin sub-type receptor 4 or human somatostatin sub-type receptor 5.

162. A method according to claim 143 wherein the somatostatin agonist is



or a pharmaceutically acceptable salt thereof, wherein

A¹ is a D- or L- isomer of Ala, Leu, Ile, Val, Nle, Thr, Ser, b-Nal, b-Pal, Trp, Phe, 2,4-dichloro-Phe, pentafluoro-Phe, p-X-Phe, or o-X-Phe, wherein X is CH₃, Cl, Br, F, OH, OCH₃ or NO₂;

A² is Ala, Leu, Ile, Val, Nle, Phe, b-Nal, pyridyl-Ala, Trp, 2,4-dichloro-Phe, pentafluoro-Phe, o-X-Phe, or p-X-Phe, wherein X is CH₃, Cl, Br, F, OH, OCH₃ or NO₂;

A³ is pyridyl-Ala, Trp, Phe, b-Nal, 2,4-dichloro-Phe, pentafluoro-Phe, o-X-Phe, or p-X-Phe, wherein X is CH₃, Cl, Br, F, OH, OCH₃ or NO₂;

A⁶ is Val, Ala, Leu, Ile, Nle, Thr, Abu, or Ser;

A⁷ is Ala, Leu, Ile, Val, Nle, Phe, b-Nal, pyridyl-Ala, Trp, 2,4-dichloro-Phe, pentafluoro-Phe, o-X-Phe, or p-X-Phe, wherein X is CH₃, Cl, Br, F, OH, OCH₃ or NO₂;

A⁸ is a D- or L-isomer of Ala, Leu, Ile, Val, Nle, Thr, Ser, Phe, b-Nal, pyridyl-Ala, Trp, 2,4-dichloro-Phe, pentafluoro-Phe, p-X-Phe, or o-X-Phe, wherein X is CH₃, Cl, Br, F, OH, OCH₃ or NO₂;

each R₁ and R₂, independently, is H, lower acyl or lower alkyl; and R₃ is OH or NH₂; provided that at least one of A¹ and A⁸ and one of A² and A⁷ must be an aromatic amino acid; and further provided that A¹, A², A⁷ and A⁸ cannot all be aromatic amino acids.

163. A method according to claim 143 wherein the somatostatin agonist is

H-D-Phe-p-chloro-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH₂;

H-D-Phe-p-NO₂-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;

H-D-Nal-p-chloro-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;



H-D-Phe-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-NH₂;

H-D-Phe-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;
 H-D-Phe-p-chloro-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;
 H-D-Phe-Ala-Tyr-D-Trp-Lys-Val-Ala-b-D-Nal-NH₂;
 D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-b-Nal-NH₂;
 D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-b-Nal-NH₂;
 D-b-Nal-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH₂;
 D-Phe-Cys-Phe-D-Trp-Lys-Thr-Pen-Thr-NH₂;
 D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-OH;
 D-Phe-Cys-Phe-D-Trp-Lys-Thr-Pen-Thr-OH;
 Gly-Pen-Phe-D-Trp-Lys-Thr-Cys-Thr-OH;
 Phe-Pen-Tyr-D-Trp-Lys-Thr-Cys-Thr-OH;
 Phe-Pen-Phe-D-Trp-Lys-Thr-Pen-Thr-OH;
 H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol;
 H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 H-D-Trp-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;
 H-D-Trp-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;
 H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH₂;
 H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;
 Ac-D-Phe-Lys*-Tyr-D-Trp-Lys-Val-Asp-Thr-NH₂, wherein an amide
 bridge is between Lys* and Asp;
 Ac-hArg(Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 Ac-D-hArg(Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 Ac-D-hArg(Bu)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 Ac-D-hArg(Et)₂-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 Ac-L-hArg(Et)₂-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 Ac-D-hArg(CH₂CF₃)₂-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 Ac-D-hArg(CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 Ac-D-hArg(CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH₂;
 Ac-D-hArg(CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHET;
 Ac-L-hArg(CH₂-CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 Ac-D-hArg(CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys(Me)-Thr-Cys-Thr-NH₂;
 Ac-D-hArg(CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys(Me)-Thr-Cys-Thr-NHET;
 Ac-hArg(CH₃, hexyl)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 H-hArg(hexyl₂)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;

Ac-D-hArg (Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHEt;
 Ac-D-hArg (Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH₂;
 Propionyl-D-hArg (Et)₂-Gly-Cys-Phe-D-Trp-Lys (iPr)-Thr-Cys-Thr-NH₂;
 Ac-D-J-Nal-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Gly-hArg (Et)₂-NH₂;
 Ac-D-Lys (iPr)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 Ac-D-hArg (CH₂CF₃)₂-D-hArg (CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 Ac-D-hArg (CH₂CF₃)₂-D-hArg (CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH₂;
 Ac-D-hArg (Et)₂-D-hArg (Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 Ac-Cys-Lys-Asn-4-Cl-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Ser-D-Cys-NH₂;
 Bmp-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;
 Bmp-Tyr-D-Trp-Lys-Val-Cys-Phe-NH₂;
 Bmp-Tyr-D-Trp-Lys-Val-Cys-p-Cl-Phe-NH₂;
 Bmp-Tyr-D-Trp-Lys-Val-Cys-b-Nal-NH₂;
 H-D-b-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;
 H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂;
 H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-b-Nal-NH₂;
 H-pentafluoro-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;
 Ac-D-b-Nal-Cys-pentafluoro-Phe-D-Trp-Lys-Val-Cys-Thr-NH₂;
 H-D-b-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-b-Nal-NH₂;
 H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-b-Nal-NH₂;
 H-D-b-Nal-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂;
 H-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂;
 Ac-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂;
 H-D-Phe-Cys-b-Nal-D-Trp-Lys-Val-Cys-Thr-NH₂;
 H-D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH₂;
 cyclo (Pro-Phe-D-Trp-N-Me-Lys-Thr-Phe);
 cyclo (Pro-Phe-D-Trp-N-Me-Lys-Thr-Phe);
 cyclo (Pro-Phe-D-Trp-Lys-Thr-N-Me-Phe);
 cyclo (N-Me-Ala-Tyr-D-Trp-Lys-Thr-Phe);
 cyclo (Pro-Tyr-D-Trp-Lys-Thr-Phe);
 cyclo (Pro-Phe-D-Trp-Lys-Thr-Phe);
 cyclo (Pro-Phe-L-Trp-Lys-Thr-Phe);
 cyclo (Pro-Phe-D-Trp (F)-Lys-Thr-Phe);
 cyclo (Pro-Phe-Trp (F)-Lys-Thr-Phe);

cyclo (Pro-Phe-D-Trp-Lys-Ser-Phe) ;
 cyclo (Pro-Phe-D-Trp-Lys-Thr-p-Cl-Phe) ;
 cyclo (D-Ala-N-Me-D-Phe-D-Thr-D-Lys-Trp-D-Phe) ;
 cyclo (D-Ala-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Phe) ;
 cyclo (D-Ala-N-Me-D-Phe-D-Thr-Lys-D-Trp-D-Phe) ;
 cyclo (D-Abu-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Tyr) ;
 cyclo (Pro-Tyr-D-Trp-t-4-AchxAla-Thr-Phe) ;
 cyclo (Pro-Phe-D-Trp-t-4-AchxAla-Thr-Phe) ;
 cyclo (N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe) ;
 cyclo (N-Me-Ala-Tyr-D-Trp-t-4-AchxAla-Thr-Phe) ;
 cyclo (Pro-Tyr-D-Trp-4-Amphe-Thr-Phe) ;
 cyclo (Pro-Phe-D-Trp-4-Amphe-Thr-Phe) ;
 cyclo (N-Me-Ala-Tyr-D-Trp-4-Amphe-Thr-Phe) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba-Gaba) ;
 cyclo (Asn-Phe-D-Trp-Lys-Thr-Phe) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-NH(CH₂)₄CO) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-b-Ala) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-D-Glu)-OH ;
 cyclo (Phe-Phe-D-Trp-Lys-Thr-Phe) ;
 cyclo (Phe-Phe-D-Trp-Lys-Thr-Phe-Gly) ;
 cyclo (Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gly) ;
 cyclo (Asn-Phe-Phe-D-Trp(F)-Lys-Thr-Phe-Gaba) ;
 cyclo (Asn-Phe-Phe-D-Trp(NO₂)-Lys-Thr-Phe-Gaba) ;
 cyclo (Asn-Phe-Phe-Trp(Br)-Lys-Thr-Phe-Gaba) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe(I)-Gaba) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Tyr(But)-Gaba) ;
 cyclo (Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Pro-Cys)-OH ;
 cyclo (Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Pro-Cys)-OH ;
 cyclo (Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Tpo-Cys)-OH ;
 cyclo (Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-MeLeu-Cys)-OH ;
 cyclo (Phe-Phe-D-Trp-Lys-Thr-Phe-Phe-Gaba) ;
 cyclo (Phe-Phe-D-Trp-Lys-Thr-Phe-D-Phe-Gaba) ;
 cyclo (Phe-Phe-D-Trp(5F)-Lys-Thr-Phe-Phe-Gaba) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys(Ac)-Thr-Phe-NH-(CH₂)₃-CO) ;

cyclo (Lys-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba);
 cyclo (Lys-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba);
 cyclo (Orn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba);
 D-b-Nal-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 H-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH₂;



or D-Phe-cyclo(Cys-Phe-D-Trp-Lys-Thr-Cys)-Thr-ol; or
 a pharmaceutically acceptable salt thereof.

164. A method according to claim 145 wherein the fibrosis induced by a drug or a combination of drugs is in the kidney, in the lung, in the liver, in the skin, of the central nervous system, in bone or bone marrow, in the cardiovascular system, in an endocrine organ, or in the gastro-intestinal system.

165. A method according to claim 145 wherein the fibrosis induced by a disease state is in the kidney, in the lung, in the liver, in the skin, of the central nervous system, in bone or bone marrow, in the cardiovascular system, in an endocrine organ, or in the gastro-intestinal system.

166. A method according to claim 145 wherein the fibrosis induced by an environmental or an industrial factor is in the kidney, in the lung, in the liver, in the skin, of the central nervous system, in bone or bone marrow, in the cardiovascular system, in an endocrine organ, or in the gastro-intestinal system.

167. A method according to claim 145 wherein the fibrosis induced by an immune reaction is in the kidney, in the lung, in the liver, in the skin of the central nervous system, in bone or bone marrow, in the cardiovascular system, in an endocrine organ, in the gastro-intestinal system.

168. A method according to claim 145 wherein the fibrosis induced by a wound is in the kidney, in the lung, in the liver, in the skin, of the central nervous system, in bone or bone marrow, in the cardiovascular system, in an endocrine organ, or in the gastrointestinal system.

169. A pharmaceutical composition useful for inhibiting fibrosis in a patient which comprises a pharmaceutically acceptable carrier and an effective amount of somatostatin or a somatostatin agonist, or a pharmaceutically acceptable salt thereof.

170. A pharmaceutical composition according to claim 169 wherein the composition comprises a somatostatin agonist or a pharmaceutically acceptable salt thereof.

171. A pharmaceutical composition useful for inhibiting overexpression of TGF-J which comprises a pharmaceutically acceptable carrier and an effective amount of somatostatin or a somatostatin agonist, or a pharmaceutically acceptable salt thereof.

172. A pharmaceutical composition according to claim 171 wherein the composition comprises a somatostatin agonist or a pharmaceutically acceptable salt thereof. --

REMARKS

Claims 1 through 141 have been cancelled and claims 142 through 172 have been added. Replacement pages 39 through 52 of new claims are provided for the examiner's convenience. No new matter has been added by the above amendments. Please apply any charges not covered to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 3-1-99

Y. Rocky Tsao
Y. Rocky Tsao
Reg. No. 34,053

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804
Telephone: 617/542-5070
358155.B11

CLAIMS

What is claimed is:

- 5 142. A method of inhibiting fibrosis in a patient said method comprising administering a therapeutically effective amount of somatostatin or a somatostatin agonist to said patient.
- 10 143. A method of claim 142, wherein said method comprises administering a therapeutically effective amount of a somatostatin agonist to said patient.
- 15 144. A method of claim 143, wherein said fibrosis is in the kidney, in the lung, in the liver, in the skin, of the central nervous system, in bone or bone marrow, in the cardiovascular system, in an endocrine organ and or in the gastro-intestinal system.
- 20 145. A method of claim 143, wherein said fibrosis is induced by chemotherapy, induced by radiation, induced by a drug or a combination of drugs, induced by a disease state, induced by an environmental or an industrial factor, induced by an immune reaction, or induced by a wound.
- 25 146. A method of claim 143, wherein said somatostatin agonist is administered parenterally.
147. A method of claim 146, wherein said somatostatin agonist is administered in a sustained release formulation.
- 30 148. A method of claim 144, wherein said somatostatin agonist is administered parenterally.
149. A method of claim 148, wherein said somatostatin agonist is administered in a sustained release formulation.
150. A method of claim 143, wherein said somatostatin agonist is administered topically or orally.
151. A method according to claim 144 wherein the fibrotic disorder in the kidney is glomerulonephritis, diabetic nephropathy, allograft rejection or HIV nephropathy; the fibrotic disorder in the lung is idiopathic fibrosis or

autoimmune fibrosis; the fibrotic disorder in the liver is cirrhosis or veno-occlusive disease; the fibrotic disorder in the skin is systemic sclerosis, keloids, burn scars or eosinophilia-myalgia syndrome and the fibrotic disorder in the
5 central nervous system is intraocular fibrosis.

152. A method according to claim 145 wherein the fibrosis induced by chemotherapy is in the kidney, in the lung, in the liver, in the skin, of the central nervous system, in bone or bone marrow, in the cardiovascular system, in an endocrine
10 organ or in the gastro-intestinal system.

153. A method according to claim 145 wherein the fibrosis induced by radiation is in the kidney, in the lung, in the liver, in the skin, of the central nervous system, in bone or bone marrow, in the cardiovascular system, in an endocrine
15 organ or in the gastro-intestinal system.

154. A method of inhibiting over-expression of TGF- β which comprises administering to a subject an effective amount of somatostatin or a somatostatin agonist, or a pharmaceutically acceptable salt thereof.


20 155. A method according to claim 154 wherein a somatostatin agonist or a pharmaceutically acceptable salt thereof is administered.

156. A method according to claim 155 wherein the somatostatin agonist has a higher binding affinity for human
25 somatostatin sub-type receptor 1, has a higher binding affinity for human somatostatin sub-type receptor 2, has a higher binding affinity for human somatostatin sub-type receptor 3, has a higher binding affinity for human somatostatin sub-type receptor 4, or has a higher binding affinity for human
30 somatostatin sub-type receptor 5.

157. A method according to claim 155 wherein the somatostatin agonist has a higher binding affinity for two or more of human somatostatin sub-type receptor 1, human somatostatin sub-type receptor 2, human somatostatin sub-type

receptor 3, human somatostatin sub-type receptor 4 or human somatostatin sub-type receptor 5.

158. A method according to claim 155 wherein the somatostatin agonist is



or a pharmaceutically acceptable salt thereof, wherein

A^1 is a D- or L- isomer of Ala, Leu, Ile, Val, Nle, Thr, Ser, J-Nal, J-Pal, Trp, Phe, 2,4-dichloro-Phe, pentafluoro-Phe, p-X-Phe, or o-X-Phe, wherein X is CH_3 , Cl, Br, F, OH, OCH_3 ,
15 or NO_2 ;

A^2 is Ala, Leu, Ile, Val, Nle, Phe, J-Nal, pyridyl-Ala, Trp, 2,4-dichloro-Phe, pentafluoro-Phe, o-X-Phe, or p-X-Phe, wherein X is CH_3 , Cl, Br, F, OH, OCH_3 or NO_2 ;

A^3 is pyridyl-Ala, Trp, Phe, J-Nal, 2,4-dichloro-Phe, pentafluoro-Phe, o-X-Phe, or p-X-Phe, wherein X is CH_3 , Cl, Br, F, OH, OCH_3 or NO_2 ;

20

A^6 is Val, Ala, Leu, Ile, Nle, Thr, Abu, or Ser;

A^7 is Ala, Leu, Ile, Val, Nle, Phe, J-Nal, pyridyl-Ala, Trp, 2,4-dichloro-Phe, pentafluoro-Phe, o-X-Phe, or p-X-Phe, wherein X is CH_3 , Cl, Br, F, OH, OCH_3 or NO_2 ;

25

A^8 is a D- or L-isomer of Ala, Leu, Ile, Val, Nle, Thr, Ser, Phe, J-Nal, pyridyl-Ala, Trp, 2,4-dichloro-Phe, pentafluoro-Phe, p-X-Phe, or o-X-Phe, wherein X is CH_3 , Cl, Br, F, OH, OCH_3 or NO_2 ;

30 each R_1 and R_2 , independently, is H, lower acyl or lower alkyl; and R_3 is OH or NH_2 ; provided that at least one of A^1 and A^8 and one of A^2 and A^7 must be an aromatic amino acid; and further provided that A^1 , A^2 , A^7 and A^8 cannot all be aromatic amino acids.

35


159. A method according to claim 155 wherein the somatostatin agonist is

- H-D-Phe-p-chloro-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH₂;
H-D-Phe-p-NO₂-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;
5 H-D-Nal-p-chloro-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;
H-D-Phe-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-NH₂;
H-D-Phe-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;
H-D-Phe-p-chloro-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;
H-D-Phe-Ala-Tyr-D-Trp-Lys-Val-Ala-J-D-Nal-NH₂;
10 D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-b-Nal-NH₂;
D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-b-Nal-NH₂;
D-b-Nal-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH₂;
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Pen-Thr-NH₂;
15 D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-OH;
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Pen-Thr-OH;
Gly-Pen-Phe-D-Trp-Lys-Thr-Cys-Thr-OH;
Phe-Pen-Tyr-D-Trp-Lys-Thr-Cys-Thr-OH;
Phe-Pen-Phe-D-Trp-Lys-Thr-Pen-Thr-OH;
20 H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol;
H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
H-D-Trp-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;
H-D-Trp-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;
25 H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH₂;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;
Ac-D-Phe-Lys*-Tyr-D-Trp-Lys-Val-Asp-Thr-NH₂, wherein an amide bridge is between Lys* and Asp;
Ac-hArg(Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
30 Ac-D-hArg(Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
Ac-D-hArg(Bu)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
Ac-D-hArg(Et)₂-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
Ac-L-hArg(Et)₂-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
Ac-D-hArg(CH₂CF₃)₂-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;


- Ac-D-hArg (CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 Ac-D-hArg (CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH₂;
 Ac-D-hArg (CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHET;
 Ac-L-hArg (CH₂-CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 5 Ac-D-hArg (CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys (Me) -Thr-Cys-Thr-NH₂;
 Ac-D-hArg (CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys (Me) -Thr-Cys-Thr-NHET;
 Ac-hArg (CH₃, hexyl) -Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 H-hArg (hexyl)₂ -Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 Ac-D-hArg (Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHET;
 10 Ac-D-hArg (Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH₂;
 Propionyl-D-hArg (Et)₂-Gly-Cys-Phe-D-Trp-Lys (iPr) -Thr-Cys-Thr-NH₂;
 Ac-D-J-Nal-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Gly-hArg (Et)₂-NH₂;
 Ac-D-Lys (iPr) -Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 15 Ac-D-hArg (CH₂CF₃)₂-D-hArg (CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 Ac-D-hArg (CH₂CF₃)₂-D-hArg (CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH₂;
 Ac-D-hArg (Et)₂-D-hArg (Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 20 Ac-Cys-Lys-Asn-4-Cl-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Ser-D-Cys-NH₂;
 Bmp-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;
 Bmp-Tyr-D-Trp-Lys-Val-Cys-Phe-NH₂;
 25 Bmp-Tyr-D-Trp-Lys-Val-Cys-p-Cl-Phe-NH₂;
 Bmp-Tyr-D-Trp-Lys-Val-Cys-b-Nal-NH₂;
 H-D-b-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;
 H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂;
 H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-b-Nal-NH₂;
 30 H-pentafluoro-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;
 Ac-D-b-Nal-Cys-pentafluoro-Phe-D-Trp-Lys-Val-Cys-Thr-NH₂;
 H-D-b-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-b-Nal-NH₂;
 H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-b-Nal-NH₂;
 H-D-b-Nal-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂;

- H-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂;
Ac-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂;
H-D-Phe-Cys-b-Nal-D-Trp-Lys-Val-Cys-Thr-NH₂;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH₂;
- 5 cyclo (Pro-Phe-D-Trp-N-Me-Lys-Thr-Phe) ;
cyclo (Pro-Phe-D-Trp-N-Me-Lys-Thr-Phe) ;
cyclo (Pro-Phe-D-Trp-Lys-Thr-N-Me-Phe) ;
cyclo (N-Me-Ala-Tyr-D-Trp-Lys-Thr-Phe) ;
cyclo (Pro-Tyr-D-Trp-Lys-Thr-Phe) ;
- 10 cyclo (Pro-Phe-D-Trp-Lys-Thr-Phe) ;
cyclo (Pro-Phe-L-Trp-Lys-Thr-Phe) ;
cyclo (Pro-Phe-D-Trp(F)-Lys-Thr-Phe) ;
cyclo (Pro-Phe-Trp(F)-Lys-Thr-Phe) ;
cyclo (Pro-Phe-D-Trp-Lys-Ser-Phe) ;
- 15 cyclo (Pro-Phe-D-Trp-Lys-Thr-p-Cl-Phe) ;
cyclo (D-Ala-N-Me-D-Phe-D-Thr-D-Lys-Trp-D-Phe) ;
cyclo (D-Ala-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Phe) ;
cyclo (D-Ala-N-Me-D-Phe-D-Thr-Lys-D-Trp-D-Phe) ;
cyclo (D-Abu-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Tyr) ;
- 20 cyclo (Pro-Tyr-D-Trp-t-4-AchxAla-Thr-Phe) ;
cyclo (Pro-Phe-D-Trp-t-4-AchxAla-Thr-Phe) ;
cyclo (N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe) ;
cyclo (N-Me-Ala-Tyr-D-Trp-t-4-AchxAla-Thr-Phe) ;
cyclo (Pro-Tyr-D-Trp-4-Amphe-Thr-Phe) ;
- 25 cyclo (Pro-Phe-D-Trp-4-Amphe-Thr-Phe) ;
cyclo (N-Me-Ala-Tyr-D-Trp-4-Amphe-Thr-Phe) ;
cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba) ;
cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba-Gaba) ;
cyclo (Asn-Phe-D-Trp-Lys-Thr-Phe) ;
- 30 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-NH(CH₂)₄CO) ;
cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-b-Ala) ;
cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-D-Glu)-OH;
cyclo (Phe-Phe-D-Trp-Lys-Thr-Phe) ;
cyclo (Phe-Phe-D-Trp-Lys-Thr-Phe-Gly) ;

- cyclo (Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gly) ;
 cyclo (Asn-Phe-Phe-D-Trp (F) -Lys-Thr-Phe-Gaba) ;
 cyclo (Asn-Phe-Phe-D-Trp (NO₂) -Lys-Thr-Phe-Gaba) ;
 5 cyclo (Asn-Phe-Phe-Trp (Br) -Lys-Thr-Phe-Gaba) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe (I) -Gaba) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Tyr (But) -Gaba) ;
 cyclo (Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Pro-Cys) -OH;
 cyclo (Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Pro-Cys) -OH;
 10 cyclo (Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Tpo-Cys) -OH;
 cyclo (Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-MeLeu-Cys) -
 OH;
 cyclo (Phe-Phe-D-Trp-Lys-Thr-Phe-Phe-Gaba) ;
 cyclo (Phe-Phe-D-Trp-Lys-Thr-Phe-D-Phe-Gaba) ;
 15 cyclo (Phe-Phe-D-Trp (5F) -Lys-Thr-Phe-Phe-Gaba) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys (Ac) -Thr-Phe-NH- (CH₂)₃-CO) ;
 cyclo (Lys-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba) ;
 cyclo (Lys-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba) ;
 cyclo (Orn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba) ;
 20 D-b-Nal-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 H-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH₂;



25




- 30 or D-Phe-cyclo(Cys-Phe-D-Trp-Lys-Thr-Cys)-Thr-ol; or
 a pharmaceutically acceptable salt thereof.

160. A method according to claim 143 wherein the somatostatin agonist has a higher binding affinity for human somatostatin sub-type receptor 1, has a higher binding affinity for human somatostatin sub-type receptor 2, has a higher binding affinity for human somatostatin sub-type receptor 3, has a higher binding affinity for human somatostatin sub-type receptor 4, or has a higher binding affinity for human somatostatin sub-type receptor 5.

161. A method according to claim 143 wherein the somatostatin agonist has a higher binding affinity for two or more of human somatostatin sub-type receptor 1, human somatostatin sub-type receptor 2, human somatostatin sub-type receptor 3, human somatostatin sub-type receptor 4 or human somatostatin sub-type receptor 5.

162. A method according to claim 143 wherein the somatostatin agonist is



or a pharmaceutically acceptable salt thereof, wherein

A^1 is a D- or L- isomer of Ala, Leu, Ile, Val, Nle, Thr, Ser, b-Nal, b-Pal, Trp, Phe, 2,4-dichloro-Phe, pentafluoro-Phe, p-X-Phe, or o-X-Phe, wherein X is CH_3 , Cl, Br, F, OH, OCH_3 or NO_2 ;

A^2 is Ala, Leu, Ile, Val, Nle, Phe, b-Nal, pyridyl-Ala, Trp, 2,4-dichloro-Phe, pentafluoro-Phe, o-X-Phe, or p-X-Phe, wherein X is CH_3 , Cl, Br, F, OH, OCH_3 or NO_2 ;

A^3 is pyridyl-Ala, Trp, Phe, b-Nal, 2,4-dichloro-Phe, pentafluoro-Phe, o-X-Phe, or p-X-Phe, wherein X is CH_3 , Cl, Br, F, OH, OCH_3 or NO_2 ;

A^6 is Val, Ala, Leu, Ile, Nle, Thr, Abu, or Ser;

A^7 is Ala, Leu, Ile, Val, Nle, Phe, b-Nal, pyridyl-Ala, Trp, 2,4-dichloro-Phe, pentafluoro-Phe, o-X-Phe, or p-X-Phe,

wherein X is CH₃, Cl, Br, F, OH, OCH₃ or NO₂;

A⁸ is a D- or L-isomer of Ala, Leu, Ile, Val, Nle, Thr, Ser, Phe, b-Nal, pyridyl-Ala, Trp, 2,4-dichloro-Phe, pentafluoro-Phe, p-X-Phe, or o-X-Phe, wherein X is CH₃, Cl, Br, F, OH, OCH₃ or NO₂;

each R₁ and R₂, independently, is H, lower acyl or lower alkyl; and R₃ is OH or NH₂; provided that at least one of A¹ and A⁸ and one of A² and A⁷ must be an aromatic amino acid; and further provided that A¹, A², A⁷ and A⁸ cannot all be aromatic amino acids.


163. A method according to claim 143 wherein the somatostatin agonist is

- H-D-Phe-p-chloro-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH₂;
H-D-Phe-p-NO₂-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;
15 H-D-Nal-p-chloro-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;
H-D-Phe-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-NH₂;
H-D-Phe-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;
H-D-Phe-p-chloro-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;
H-D-Phe-Ala-Tyr-D-Trp-Lys-Val-Ala-b-D-Nal-NH₂;
20 D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-b-Nal-NH₂;
D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-b-Nal-NH₂;
D-b-Nal-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH₂;
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Pen-Thr-NH₂;
25 D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-OH;
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Pen-Thr-OH;
Gly-Pen-Phe-D-Trp-Lys-Thr-Cys-Thr-OH;
Phe-Pen-Tyr-D-Trp-Lys-Thr-Cys-Thr-OH;
Phe-Pen-Phe-D-Trp-Lys-Thr-Pen-Thr-OH;
30 H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol;
H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
H-D-Trp-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;
H-D-Trp-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;


- H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH₂;
H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;
Ac-D-Phe-Lys*-Tyr-D-Trp-Lys-Val-Asp-Thr-NH₂, wherein an amide bridge is between Lys* and Asp;
- 5 Ac-hArg(Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
Ac-D-hArg(Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
Ac-D-hArg(Bu)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
Ac-D-hArg(Et)₂-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
Ac-L-hArg(Et)₂-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
- 10 Ac-D-hArg(CH₂CF₃)₂-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
Ac-D-hArg(CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
Ac-D-hArg(CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH₂;
Ac-D-hArg(CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHET;
Ac-L-hArg(CH₂-CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
- 15 Ac-D-hArg(CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys(Me)-Thr-Cys-Thr-NH₂;
Ac-D-hArg(CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys(Me)-Thr-Cys-Thr-NHET;
Ac-hArg(CH₃, hexyl)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
H-hArg(hexyl)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
Ac-D-hArg(Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHET;
- 20 Ac-D-hArg(Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH₂;
Propionyl-D-hArg(Et)₂-Gly-Cys-Phe-D-Trp-Lys(iPr)-Thr-Cys-Thr-NH₂;
Ac-D-J-Nal-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Gly-hArg(Et)₂-NH₂;
Ac-D-Lys(iPr)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
- 25 Ac-D-hArg(CH₂CF₃)₂-D-hArg(CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH₂;
Ac-D-hArg(CH₂CF₃)₂-D-hArg(CH₂CF₃)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH₂;
Ac-D-hArg(Et)₂-D-hArg(Et)₂-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-
- 30 NH₂;
Ac-Cys-Lys-Asn-4-Cl-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Ser-D-Cys-NH₂;
Bmp-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;
Bmp-Tyr-D-Trp-Lys-Val-Cys-Phe-NH₂;

- Bmp-Tyr-D-Trp-Lys-Val-Cys-p-Cl-Phe-NH₂;
 Bmp-Tyr-D-Trp-Lys-Val-Cys-b-Nal-NH₂;
 H-D-b-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;
 H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂;
 5 H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-b-Nal-NH₂;
 H-pentafluoro-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂;
 Ac-D-b-Nal-Cys-pentafluoro-Phe-D-Trp-Lys-Val-Cys-Thr-NH₂;
 H-D-b-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-b-Nal-NH₂;
 H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-b-Nal-NH₂;
 10 H-D-b-Nal-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂;
 H-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂;
 Ac-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂;
 H-D-Phe-Cys-b-Nal-D-Trp-Lys-Val-Cys-Thr-NH₂;
 H-D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH₂;
 15 cyclo (Pro-Phe-D-Trp-N-Me-Lys-Thr-Phe) ;
 cyclo (Pro-Phe-D-Trp-N-Me-Lys-Thr-Phe) ;
 cyclo (Pro-Phe-D-Trp-Lys-Thr-N-Me-Phe) ;
 cyclo (N-Me-Ala-Tyr-D-Trp-Lys-Thr-Phe) ;
 cyclo (Pro-Tyr-D-Trp-Lys-Thr-Phe) ;
 20 cyclo (Pro-Phe-D-Trp-Lys-Thr-Phe) ;
 cyclo (Pro-Phe-L-Trp-Lys-Thr-Phe) ;
 cyclo (Pro-Phe-D-Trp(F)-Lys-Thr-Phe) ;
 cyclo (Pro-Phe-Trp(F)-Lys-Thr-Phe) ;
 cyclo (Pro-Phe-D-Trp-Lys-Ser-Phe) ;
 25 cyclo (Pro-Phe-D-Trp-Lys-Thr-p-Cl-Phe) ;
 cyclo (D-Ala-N-Me-D-Phe-D-Thr-D-Lys-Trp-D-Phe) ;
 cyclo (D-Ala-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Phe) ;
 cyclo (D-Ala-N-Me-D-Phe-D-Thr-Lys-D-Trp-D-Phe) ;
 cyclo (D-Abu-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Tyr) ;
 30 cyclo (Pro-Tyr-D-Trp-t-4-AchxAla-Thr-Phe) ;
 cyclo (Pro-Phe-D-Trp-t-4-AchxAla-Thr-Phe) ;
 cyclo (N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe) ;
 cyclo (N-Me-Ala-Tyr-D-Trp-t-4-AchxAla-Thr-Phe) ;
 cyclo (Pro-Tyr-D-Trp-4-Amphe-Thr-Phe) ;

- cyclo (Pro-Phe-D-Trp-4-Amphe-Thr-Phe) ;
 cyclo (N-Me-Ala-Tyr-D-Trp-4-Amphe-Thr-Phe) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba-Gaba) ;
 5 cyclo (Asn-Phe-D-Trp-Lys-Thr-Phe) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-NH(CH₂)₄CO) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-b-Ala) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-D-Glu) -OH;
 cyclo (Phe-Phe-D-Trp-Lys-Thr-Phe) ;
 10 cyclo (Phe-Phe-D-Trp-Lys-Thr-Phe-Gly) ;
 cyclo (Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gly) ;
 cyclo (Asn-Phe-Phe-D-Trp(F) -Lys-Thr-Phe-Gaba) ;
 cyclo (Asn-Phe-Phe-D-Trp(NO₂) -Lys-Thr-Phe-Gaba) ;
 15 cyclo (Asn-Phe-Phe-Trp(Br) -Lys-Thr-Phe-Gaba) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Phe(I) -Gaba) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys-Thr-Tyr(But) -Gaba) ;
 cyclo (Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Pro-Cys) -OH;
 cyclo (Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Pro-Cys) -OH;
 20 cyclo (Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Tpo-Cys) -OH;
 cyclo (Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-MeLeu-Cys) -OH;
 cyclo (Phe-Phe-D-Trp-Lys-Thr-Phe-Phe-Gaba) ;
 cyclo (Phe-Phe-D-Trp-Lys-Thr-Phe-D-Phe-Gaba) ;
 25 cyclo (Phe-Phe-D-Trp(5F) -Lys-Thr-Phe-Phe-Gaba) ;
 cyclo (Asn-Phe-Phe-D-Trp-Lys(Ac) -Thr-Phe-NH-(CH₂)₃-CO) ;
 cyclo (Lys-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba) ;
 cyclo (Lys-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba) ;
 cyclo (Orn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba) ;
 30 D-b-Nal-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH₂;
 H-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH₂;



5



or D-Phe-cyclo(Cys-Phe-D-Trp-Lys-Thr-Cys)-Thr-ol; or
10 a pharmaceutically acceptable salt thereof.

164. A method according to claim 145 wherein the fibrosis
induced by a drug or a combination of drugs is in the kidney,
in the lung, in the liver, in the skin, of the central nervous
system, in bone or bone marrow, in the cardiovascular system,
15 in an endocrine organ, or in the gastro-intestinal system.

165. A method according to claim 145 wherein the fibrosis
induced by a disease state is in the kidney, in the lung, in
the liver, in the skin, of the central nervous system, in bone
or bone marrow, in the cardiovascular system, in an endocrine
20 organ, or in the gastro-intestinal system.

166. A method according to claim 145 wherein the fibrosis
induced by an environmental or an industrial factor is in the
kidney, in the lung, in the liver, in the skin, of the central
nervous system, in bone or bone marrow, in the cardiovascular
25 system, in an endocrine organ, or in the gastro-intestinal
system.

167. A method according to claim 145 wherein the fibrosis
induced by an immune reaction is in the kidney, in the lung, in
the liver, in the skin of the central nervous system, in bone
or bone marrow, in the cardiovascular system, in an endocrine
30 organ, in the gastro-intestinal system.

168. A method according to claim 145 wherein the fibrosis
induced by a wound is in the kidney, in the lung, in the liver,
in the skin, of the central nervous system, in bone or bone

marrow, in the cardiovascular system, in an endocrine organ, or in the gastrointestinal system.

169. A pharmaceutical composition useful for inhibiting fibrosis in a patient which comprises a pharmaceutically acceptable carrier and an effective amount of somatostatin or a somatostatin agonist, or a pharmaceutically acceptable salt thereof.

170. A pharmaceutical composition according to claim 169 wherein the composition comprises a somatostatin agonist or a pharmaceutically acceptable salt thereof.

171. A pharmaceutical composition useful for inhibiting overexpression of TGF-J which comprises a pharmaceutically acceptable carrier and an effective amount of somatostatin or a somatostatin agonist, or a pharmaceutically acceptable salt thereof.

172. A pharmaceutical composition according to claim 171 wherein the composition comprises a somatostatin agonist or a pharmaceutically acceptable salt thereof.